Cardiology fellow in the Lusis Lab @UCLA. Partner to @DemetraHufnagel. Bluesky: https://xitter.cf/t.co/rCEDp2MxpY
Los Angeles, CA
Joined March 2009
- Tweets2.1K
- Following1.4K
- Followers1.1K
- Likes4.1K
Michael Raddatz retweeted
ICI #myocarditis can present late & atypically. Biventricular ICI-M w/ predominant RV failure 17 months after pembrolizumab, a reminder to maintain long-term vigilance for #cardiotoxicity beyond the early Tx period. jacc.org/doi/10.1016/j.jacca…
#JACCCardioOnc @datsunian @MichaelR21
Michael Raddatz retweeted
New review in @CircRes! GLP-1R agonists are more than weight loss drugs — we explore how they reshape lipoprotein metabolism & adipose tissue to reduce CV risk beyond adiposity.
doi.org/10.1161/CIRCRESAHA.1…
#GLP1 #Cardiology #Lipids
Michael Raddatz retweeted
🎉Check out our largest CHIP GWAS to date of >1M participants, shedding light on how germline variation governs which somatic clones in blood expand with aging🧬
In parallel, we conducted CHIP PheWAS, linking CHIP to hematologic, cardiovascular, infectious, and other conditions🩸🫀🦠 medrxiv.org/content/10.1101/…
@M_Mesbah_Uddin @AlexBickMDPhD @pnatarajanmd
Our preprint led by @M_Mesbah_Uddin @ZhiYu_ACGT and with @AlexBickMDPhD describes the germline genetic drivers and phenotypic associations of clonal hematopoiesis of indeterminate potential across >1M individuals medrxiv.org/content/10.1101/… @medrxivpreprint
Michael Raddatz retweeted
Very excited to share our study spearheaded by A. Misra & @AniruddhPatelMD describing the development & validation of our clinical multi-CVD polygenic risk score test, including how it might inform CVD prevention sciencedirect.com/science/ar… @JACCJournals
Any clinician can order this @MassGenBrigham @broadinstitute test today: massgeneralbrigham.org/en/re…
We used an integrated framework we previously developed and described to maximize performance and score stability, and allow for versioning as genomic interpretation continually improves.
cell.com/cell-genomics/fullt…
nature.com/articles/s41467-0…
The score was optimized in the nationwide @NIH @AllofUsResearch Program to enhance generalizability across communities, with validation in the @MassGenBrigham Biobank
@amandajowell @buutrg @aklfahed @shaan_khurshid @patrick_ellinor @nialljlennon @HornsbyWhitney @EWkarlson
Michael Raddatz retweeted
Go #bruinhearts #cardioonc @A_SteinMerlob!!
Thank you @CASivaram1 for supporting national stars!
@uclaCVfellows @gcfmd @kewatson @MichaelR21 @qicong_sheng @RachelOhmanMD @IntMedAbel @DOM_UCLA @ZainAsadCardOnc
#OUCVGR
🤩 Delighted to host Dr. Ashley Stein-Merlob MD PhD from UCLA at Virtual OU CVGR on 4/23/2026 at 7.15 am
🤩 Join us to learn about advances in targeted treatment of TTR Cardiac Amyloidosis
oklahoma.zoom.us/j/938070828…
@OUCollegeofMed
@datsunian
@BrettSperryMD
@A_SteinMerlob
@MKIttlesonMD
@ShashankSinhaMD
@JasonKatzMD
@HeartOTXHeartMD
@MarthaGrogan1
@DrMarthaGulati
@iamritu
@ZainAsadCardOnc
@noshreza
Michael Raddatz retweeted
A cholesterol AND #cardioonc curveball…& newly described IRAE?
#STAR future #bruinhearts chief @repettigiuliana Stumps the Profs w/ a ⁉️case of rapidly ⬆️ lipids after ICI myocarditis/hepatitis w/cholestatic injury ➡️ lipoprotein X!🤯 How 2 🔎?
🙏 to #ACCFIT chairs! #ACC26
Michael Raddatz retweeted
Great @NatRevCardiol review by @uclaCVfellows #bruinhearts chief @MichaelR21, @A_SteinMerlob & @UCLAHealthJCCC #cardioonc colleagues 🔎how cellular therapies impact♥️health.
Many avenues to 🔎 as this evolving bioimmunotechnology as cancer indications⬆️
rdcu.be/e5k6t
Glad to see this collaborative effort with @datsunian @A_SteinMerlob and our wonderful coauthors online!
Glad to see this collaborative effort with @datsunian @A_SteinMerlob and our wonderful coauthors online!
Exciting research news!
DoM fellow, Dr. Michael Raddatz, and his team published groundbreaking research in @JClinicalInvest uncovering how CHIP mutations increase the risk of aortic valve disease. Their work could lead to new preventive treatments: uclahs.fyi/49JfFhi
Michael Raddatz retweeted
@rheumrob,@AlexBickMDPhD, & I are excited to share that our work is now out in @jclinicalinvest! CHIP epi studies underestimate the association between CHIP & disease using WGS vs deep sequencing. Many thanks to the co-authors, participants, & reviewers! doi.org/10.1172/JCI198861
Using a unique cohort of 10k doubly sequenced people in @VUMCDiscoveries's BioVU, @AlexBickMDPhD, @yash_pershad, and I investigated how well #WGS data really works for detecting #CHIP. medrxiv.org/content/10.1101/…. Thread below! 1/n
Happy to see @jclinicalinvest highlighting our work on CHIP and aortic valve stenosis. Short thread below ⬇️
xitter.cf/MichaelR21/status/1990…
#ClonalHematopoiesis of indeterminate potential (CHIP) is common in older individuals, but its connection with aortic valve stenosis was unclear.
Here, @AlexBickMDPhD @StefanieDimmel1 @AndreasZeiher @cpi_exstra reveal an association between TET2 mutations and aortic valve stenosis (n=886,378), showing #CHIP activates procalcific pathways in macrophages and promotes aortic valve stenosis: jci.org/articles/view/171634
The figure shows increased aortic valve calcification (OSM, green) and inflammation (S100A9, red) in a CHIP TET2-mutant mouse model; nuclei (DAPI, blue).
Michael Raddatz retweeted
#ClonalHematopoiesis of indeterminate potential (CHIP) is common in older individuals, but its connection with aortic valve stenosis was unclear.
Here, @AlexBickMDPhD @StefanieDimmel1 @AndreasZeiher @cpi_exstra reveal an association between TET2 mutations and aortic valve stenosis (n=886,378), showing #CHIP activates procalcific pathways in macrophages and promotes aortic valve stenosis: jci.org/articles/view/171634
The figure shows increased aortic valve calcification (OSM, green) and inflammation (S100A9, red) in a CHIP TET2-mutant mouse model; nuclei (DAPI, blue).
Michael Raddatz retweeted
CHIP (TET2 and ASXL1 mutations) heightens risk of incident aortic stenosis through oncostatin M (OSM) signaling. OSM is in the family of IL-6 cytokines and signals through gp130 - makes me wonder what the effect of the IL-6R hypofunction variant/IL-6 blockade may be.
We still don't measure CHIP in the clinic (blood stem cell clones) which occur frequently with age and are a risk factor for cancer and heart disease. Here's how CHIP can lead to a calcified aortic valve. @jclinicalinvest
jci.org/articles/view/171634
Thanks for sharing, @EricTopol! Glad to see this story out in @jclinicalinvest. Short thread below:
We still don't measure CHIP in the clinic (blood stem cell clones) which occur frequently with age and are a risk factor for cancer and heart disease. Here's how CHIP can lead to a calcified aortic valve. @jclinicalinvest
jci.org/articles/view/171634
Excited to share, and grateful for a large team that helped push this forward over the years! @yash_pershad @DrFlashHeart @AlexSilverMSTP @vumcvalve @VanderbiltMSTP